Orofar Lidocaïne Parels (Benzoxonium Chloride, Lidocaine Hydrochloride)

Lidocaine hydrochloride blocks voltage‑gated sodium channels on peripheral nerve membranes, preventing the rapid influx of sodium ions that is required for nerve depolarisation. By inhibiting this process, lidocaine stops the transmission of pain signals, producing a reversible loss of sensation in the area where the product is applied.

The appropriate dose of Orofar Lidocaïne Parels is determined by the prescribing healthcare professional based on the specific clinical situation, patient age, and the extent of the oral area to be treated. The product is supplied for professional use, and the prescriber will provide exact instructions on the amount to apply.

Safety data for the combined use of lidocaine and benzoxonium chloride in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of this product with their physician before treatment.

To order Orofar Lidocaïne Parels, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details and any required import documentation.

Compared with single‑agent gels such as benzocaine, Orofar Lidocaïne Parels offers a dual mechanism: lidocaine provides a more potent and longer‑lasting anaesthetic effect, while benzoxonium chloride adds an antiseptic component that helps reduce microbial load. This combination can be advantageous in settings where both pain control and infection prevention are desired.

Store Orofar Lidocaïne Parels at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use to maintain stability and potency.

The product is applied directly to the oral mucosa using a sterile applicator or swab. The prescribed amount is spread evenly over the target area, allowing it to act locally. It is intended for short‑term use under professional supervision, and the patient should avoid swallowing large quantities.

The most serious risks include allergic reactions such as angioedema or anaphylaxis, systemic lidocaine toxicity that can manifest as seizures or cardiac arrhythmias, and severe mucosal ulceration. Patients should be monitored for signs of hypersensitivity or systemic effects, especially when larger amounts are applied or when used in conjunction with other local anaesthetics.

Individuals with a known hypersensitivity to lidocaine, benzoxonium chloride, or any component of the formulation should avoid this product. It is also contraindicated in patients with severe cardiac conduction disorders, those taking Class I antiarrhythmic drugs, and children under two years of age unless specifically directed by a qualified clinician.